AI assistant
Oncopeptides — Share Issue/Capital Change 2017
Feb 28, 2017
3091_rns_2017-02-28_5d8be3db-e462-4f3d-b5be-41199718761d.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
Stockholm, Sweden February 28, 2017
Change in number of shares and votes in Oncopeptides AB (publ)
During February, the number of shares and votes in Oncopeptides AB (publ) ("Oncopeptides" or the "Company") has increased by 16,786,215 shares and votes due to the new issues of shares that were made in connection with the listing of the Company's shares on Nasdaq Stockholm. As of February 28, 2017, the number of shares and votes in Oncopeptides amounts to 38,828,115.
About Oncopeptides
Oncopeptides is a research and development stage pharmaceutical company developing drugs for treatment of cancer. Since the founding of the Company in 2000, the Company has focused primarily on the development of the product candidate Ygalo, an innovative peptidase-potentiated alkylator intended for effective and focused treatment of bloodbased cancer diseases, and in particular multiple myeloma. Ygalo is intended to demonstrate better results from treatment compared to established alternative drugs in the treatment of patients with multiple myeloma. Ygalo could potentially provide treating physicians with a new treatment option for patients suffering from this severe cancer disease. Visit www.oncopeptides.se for more information.
For further information, please contact:
Jakob Lindberg, CEO at Oncopeptides E-mail: [email protected]
Rein Piir, Head of Investor Relations at Oncopeptides E-mail: [email protected]
This information is such that Oncopeptides is required to publish under the Swedish Financial Instruments Trading Act. The information was released for public disclosure, through the agency of the contact person above, on February 28, 2017 at 08.00 a.m. (CET).